Cazzola M, et al. - Via performing a meta-analysis, researchers compared the impact of triple combination therapy with inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs) vs LABA/LAMA combination or single long-acting bronchodilator therapy in chronic obstructive pulmonary disease. They noted a reduction in the risk of exacerbation and improvement in trough FEV₁ with ICS/LABA/LAMA combination vs LABA/LAMA combination. Patients with blood eosinophil counts ≥ 300 cells per µL displayed greater protective effect with triple combination therapy vs LABA/LAMA combination against the risk of exacerbation. Outcomes thus suggested that ICS/LABA/LAMA combination could benefit patients on single long-acting bronchodilator therapy or LABA/LAMA combination who still have exacerbations and have blood eosinophil count ≥ 300 cells per µL.